| 1 |
34304363 | Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism. | 2021 Jul |
7 |
| 2 |
33240461 | Single nucleotide polymorphisms on CYP2C9 gene among Filipinos and its association with post-operative pain relief via COX-2 inhibitors. | 2020 |
1 |
| 3 |
31274208 | Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. | 2019 Dec |
3 |
| 4 |
29377603 | Effects of Ojeok-san on the Pharmacokinetics of Celecoxib at Steady-state in Healthy Volunteers. | 2018 Jul |
1 |
| 5 |
29563776 | Inhibitory effect of celecoxib on agomelatine metabolism in vitro and in vivo. | 2018 |
3 |
| 6 |
30034221 | Does celecoxib inhibit agomelatine metabolism via CYP2C9 or CYP1A2? | 2018 |
1 |
| 7 |
30219715 | Celecoxib is a substrate of CYP2D6: Impact on celecoxib metabolism in individuals with CYP2C9*3 variants. | 2018 Oct |
6 |
| 8 |
27864660 | Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite. | 2017 Mar |
15 |
| 9 |
25585969 | Novel Use of Pharmacogenetic Testing in the Identification of CYP2C9 Polymorphisms Related to NSAID-Induced Gastropathy. | 2015 May |
1 |
| 10 |
26360837 | Influence of genetic polymorphisms on the pharmacokinetics of celecoxib and its two main metabolites in healthy Chinese subjects. | 2015 Nov 15 |
5 |
| 11 |
23996211 | Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib. | 2013 Dec |
4 |
| 12 |
28520369 | Celecoxib Therapy and CYP2C9 Genotype | 2012 |
4 |
| 13 |
19233181 | Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. | 2009 Jun |
4 |
| 14 |
19422321 | Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? | 2009 Jun |
2 |
| 15 |
19515014 | Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. | 2009 |
1 |
| 16 |
19925388 | Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. | 2009 Sep |
2 |
| 17 |
20167001 | New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. | 2009 Dec |
1 |
| 18 |
17999057 | Clinical use and pharmacological properties of selective COX-2 inhibitors. | 2008 Mar |
1 |
| 19 |
17696334 | CYP2C9 structure-metabolism relationships: optimizing the metabolic stability of COX-2 inhibitors. | 2007 Sep 6 |
1 |
| 20 |
16513453 | Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3. | 2006 Mar |
1 |
| 21 |
16952496 | Is celecoxib an inducer of cytochrome P450 3A4 in subjects carrying the CYP2C9*3 allele? | 2006 Sep |
1 |
| 22 |
17022718 | [Clinical pharmacogenomics for CYP2C8 and CYP2C9: general concepts and application to the use of NSAIDs]. | 2006 Jul-Aug |
1 |
| 23 |
15569819 | Cytochrome P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells. | 2005 Feb |
2 |
| 24 |
16118328 | Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? | 2005 Nov |
1 |
| 25 |
16153401 | Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient. | 2005 Sep |
1 |
| 26 |
14970301 | Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication. | 2004 Feb |
1 |
| 27 |
15058617 | Drug interactions in dentistry: the importance of knowing your CYPs. | 2004 Mar |
1 |
| 28 |
12603175 | Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. | 2003 |
1 |
| 29 |
12893985 | Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. | 2003 Aug |
8 |
| 30 |
14768975 | Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. | 2003 |
2 |
| 31 |
11816012 | Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. | 2002 Feb |
1 |
| 32 |
12392591 | Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. | 2002 Oct |
8 |
| 33 |
11337938 | In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. | 2001 Apr |
14 |
| 34 |
11601668 | Clinical implications of drug interactions with coxibs. | 2001 Oct |
2 |
| 35 |
10749518 | Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. | 2000 Mar |
2 |
| 36 |
10773015 | Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. | 2000 May |
3 |
| 37 |
10463513 | Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. | 1999 Jul |
1 |